| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Psychiatry and Behavioral Sciences (Drs. Marsh, Grill, and Munro, and J.R. Williams and M. Rocco), Department of Neurology (Drs. Marsh, Grill, and Dawson), Institute for Cell Engineering (Dr. Dawson), and Department of Neuroscience (Dr. Dawson), Morris K. Udall Parkinson’s Disease Research Center of Excellence at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD.
Address correspondence and reprint requests to Dr. Laura Marsh, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Phipps 300, Baltimore, MD 21287; e-mail: lmarsh{at}jhmi.edu
Objective: To determine the prevalence and impact of comorbid psychiatric disturbances in Parkinson disease (PD) patients with psychosis.
Methods: Subject data were derived from a research database of 116 PD patients participating in standardized motor, cognitive, psychiatric, and caregiver assessments.
Results: There were 25 patients (22%) with psychosis manifest as hallucinations (n = 9), delusions (n = 1), or hallucinations and delusions (n = 15) and 25 patients (22%) who had no current or past psychiatric comorbidities (PDN). In the psychotic group, 44% had psychosis only (PSY), and 56% had psychosis plus at least one other comorbid psychiatric disturbance (PSY+), including depressive disorders (71%), anxiety disorders (21%), apathetic syndromes (14%), and delirium (14%). There were no differences in age, sex, education, or age onset or duration of PD among the PSY, PSY+, and PDN groups. Both psychotic groups had greater motor, functional, and frontal cognitive deficits and increased caregiver burden scores relative to PDN. PSY+ showed greater global and selective cognitive deficits compared to PDN. Psychosis was a primary predictor of caregiver burden, whereas depressive symptoms indirectly enhanced motor impairments.
Conclusions: Nonpsychotic psychiatric disturbances, especially affective disturbances, are common comorbidities in PD patients with psychosis and warrant clinical attention to reduce morbidity and caregiver distress.
Received December 8, 2003. Accepted in final form March 4, 2004.
Presented in part at the Movement Disorders Society annual meeting; November 2002.
This article has been cited by other articles:
|
|
 |
|
  D. Weintraub and H. I. Hurtig Presentation and Management of Psychosis in Parkinson's Disease and Dementia With Lewy Bodies Am J Psychiatry, October 1, 2007; 164(10): 1491 - 1498. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Weintraub, D. Taraborelli, K. H. Morales, J. E. Duda, I. R. Katz, and M. B. Stern Escitalopram for Major Depression in Parkinson's Disease: An Open-Label, Flexible-Dosage Study J Neuropsychiatry Clin Neurosci, August 1, 2006; 18(3): 377 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hudry, J. O Rinne, T. Keranen, L. Eckert, and J. M Cochran Cost-Utility Model of Rasagiline in the Treatment of Advanced Parkinson's Disease in Finland Ann. Pharmacother., April 1, 2006; 40(4): 651 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Weintraub and M. B. Stern Psychiatric Complications in Parkinson Disease Am J Geriatr Psychiatry, October 1, 2005; 13(10): 844 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B R Thanvi, T C N Lo, and D P Harsh Psychosis in Parkinson's disease Postgrad. Med. J., October 1, 2005; 81(960): 644 - 646. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
